PureTech gets FDA fast track designation for LYT-200 to treat head/neck cancer

PureTech Health announced that the U.S. Food and Drug Administration or FDA has granted Fast Track designation for LYT-200 in combination with anti-PD1 therapy for the treatment of recurrent/metastatic head and neck squamous cell carcinomas or head and neck cancers. “In the U.S., there are approximately 66,000 people diagnosed with head and neck cancers each year, and the prognosis for metastatic disease is unfavorable, with a median survival rate of about ten months,” said Eric Sherman, M.D., Memorial Sloan Kettering Cancer Center and an investigator in PureTech’s Phase 1/2 clinical trial. “There is an important need to explore promising new mechanisms and targets such as galectin-9 to bring therapeutic innovation to this patient population.”